A significant breakthrough in advanced bladder cancer treatment has been approved for use on the NHS, offering renewed hope to patients and potentially doubling survival times. The innovative combination therapy, comprising enfortumab vedotin (Padcev) and pembrolizumab (Keytruda), demonstrated superior survival rates in clinical trials when compared with traditional platinum-based chemotherapy.
It is estimated that 1,250 people a year could benefit from the treatment.
